Dell and Super Micro Launch Nvidia Vera Rubin AI Servers, Sparking Fresh Market Buzz
Early shipments and bullish analyst targets signal strong 2026 growth.
Already have an account? Sign in.
Early shipments and bullish analyst targets signal strong 2026 growth.
Phase 2 data showed 77% seizure reduction and sustained benefits up to 1 year.
Entera Bio receives positive FDA feedback on its pivotal Phase 3 trial design for EB613, the potential first once-daily oral tablet to stimulate bone formation in postmenopausal women with osteoporosis.
Another major exit follows Noam Shazeer’s move to OpenAI.